

1 **An integrative analysis of clinical and epigenetic biomarkers of mortality**

2

3 Tianxiao Huan^{1,2,3,*} (tianxiao.huan@umassmed.edu),

4 Steve Nguyen^{4†} (nguy2295@umn.edu),

5 Elena Colicino⁵ (elena.colicino@mssm.edu),

6 Carolina Ochoa-Rosales⁶ (c.ochoarosales@erasmusmc.nl),

7 W. David Hill⁷ (David.Hill@ed.ac.uk),

8 Jennifer A. Brody^{8,9} (jeco@uw.edu),

9 Mette Soerensen^{10,11,12} (msoerensen@health.sdu.dk),

10 Yan Zhang¹³ (y.zhang@Dkfz-Heidelberg.de),

11 Antoine Baldassari¹⁴ (baldassa@email.unc.edu),

12 Mohamed Ahmed Elhadad^{15,16,17} (mohamed.elhadad@helmholtz-muenchen.de),

13 Tanaka Toshiko¹⁸ (tanakato@mail.nih.gov),

14 Yinan Zheng¹⁹ (y-zheng@northwestern.edu),

15 Arce Domingo-Relloso²⁰⁻²² (ad3531@cumc.columbia.edu),

16 Dong Heon Lee^{1,2} (dephs1042@gmail.com),

17 Jiantao Ma^{1,2,23} (jiantao.ma@tufts.edu),

18 Chen Yao^{1,2} (chenyao.bioinfor@gmail.com),

19 Chunyu Liu²⁴ (liuc@bu.edu),

20 Shih-Jen Hwang^{1,2} (hwangs2@nhlbi.nih.gov),

21 Roby Joehanes^{1,2} (robj.joehanes@nih.gov),

22 Myriam Fornage²⁵ (Myriam.Fornage@uth.tmc.edu),

23 Jan Bressler²⁶ (jan.bressler@uth.tmc.edu),

24 Joyce BJ van Meurs²⁶ (j.vanmeurs@erasmusmc.nl),

25 Birgit Debrabant¹⁰ (bdebrabant@health.sdu.dk),

26 Jonas Mengel-From^{10,12} (jmengel-from@health.sdu.dk),

27 Jacob Hjelmborg¹⁰ (JHjelmborg@health.sdu.dk),

28 Kaare Christensen^{10,12} (KChristensen@health.sdu.dk),

29 Pantel Vokonas²⁷⁻²⁹ (pantel.vokonas@va.gov),

30 Joel Schwartz³⁰ (joel@hsph.harvard.edu),

- 31 Sina A. Gahrib^{8,9} (sagharib@u.washington.edu),
32 Nona Sotoodehnia^{8,9} (nsotoo@uw.edu),
33 Colleen M. Sitlani^{8,9} (csitlani@uw.edu),
34 Sonja Kunze^{15,16} (sonja.kunze@helmholtz-muenchen.de),
35 Christian Gieger^{15,16,17} (christian.gieger@helmholtz-muenchen.de),
36 Annette Peters^{16,17,31,32} (peters@helmholtz-muenchen.de),
37 Melanie Waldenberger^{15,16,17} (waldenberger@helmholtz-muenchen.de),
38 Ian J. Deary⁷ (iand@exseed.ed.ac.uk),
39 Luigi Ferrucci¹⁸ (FerrucciLu@grc.nia.nih.gov),
40 Yishu Qu¹⁹ (yishu.qu@northwestern.edu),
41 Philip Greenland¹⁹ (p-greenland@northwestern.edu),
42 Donald M Lloyd-Jones¹⁹ (dlj@northwestern.edu),
43 Lifang Hou¹⁹ (l-hou@northwestern.edu),
44 Stefania Bandinelli³³ (stefania.l.bandinelli@uslcentro.toscana.it),
45 Trudy Voortman⁶ (trudy.voortman@erasmusmc.nl),
46 Brenner Hermann^{13,34} (h.brenner@Dkfz-Heidelberg.de),
47 Andrea Baccarelli³⁵ (ab4303@cumc.columbia.edu),
48 Eric Whitsel^{14,36} (eric_whitsel@med.unc.edu),
49 James S. Pankow^{4*} (panko001@umn.edu),
50 Daniel Levy^{1,2*} (levyd@nhlbi.nih.gov)

51

52

- 53 1 The Framingham Heart Study, Framingham, MA, USA
54 2 The Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute,
55 National Institutes of Health, Bethesda, MD, USA
56 3 Department of Ophthalmology and Visual Sciences, University of Massachusetts Medical School, MA, USA
57 4 Division of Epidemiology & Community Health, School of Public Health, University of Minnesota,
58 Minneapolis, MN, USA
59 5 Icahn School of Medicine at Mount Sinai, New York, NY, USA
60 6 Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
61 7 Dept of Psychology, Univ of Edinburgh, Edinburgh, UK
62 8 Division of Pulmonary, Critical Care and Sleep Medicine, Center for Lung Biology, University of
63 Washington, Seattle, WA, USA
64 9 Cardiovascular Health Research Unit, Seattle, WA, USA
65 10 Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern
66 Denmark, J.B. Winsløvs Vej 9B, 5000, Odense C, Denmark
67 11 Department of Clinical Biochemistry and Pharmacology, Center for Individualized Medicine in Arterial
68 Diseases, Odense University Hospital, J.B. Winsløvs Vej 4, 5000, Odense C, Denmark

- 69 12 Department of Clinical Genetics, Odense University Hospital, J.B. Winsløvs Vej 4, 5000, Odense C,
70 Denmark
71 13 Division of Clinical Epidemiology & Aging Research, German Cancer Rsrch Ctr (DKFZ)
72 14 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel
73 Hill, NC, 27599, USA
74 15 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for
75 Environmental Health, Neuherberg, Germany
76 16 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health,
77 Neuherberg, Germany
78 17 German Research Center for Cardiovascular Disease (DZHK), Partner site Munich Heart Alliance, Germany
79 18 Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, USA
80 19 Ctr for Population Epigenetics, Robert H. Lurie Comprehensive Cancer Ctr & Dept of Preventive Medicine,
81 Northwestern Univ Feinberg School of Medicine, Chicago, IL, USA
82 20 Department of Chronic Diseases Epidemiology, National Center for Epidemiology, Carlos III Health
83 Institute, Madrid, Spain.
84 21 Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New
85 York, NY, USA
86 22 Department of Statistics and Operations Research, University of Valencia, Spain
87 23 Nutrition Epidemiology & Data Science, Friedman School of Nutrition Science and Policy & Cardiovascular
88 Nutrition Laboratory, USDA Human Nutrition Rsrch Ctr on Aging, Tufts Univ, Boston, MA, USA
89 24 Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
90 25 Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston,
91 Houston, TX, USA
92 26 Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands
93 27 Veterans Affairs, Normative Aging Study, Boston, MA, USA
94 28 Veterans Affairs, Boston Healthcare System, Boston, MA, USA
95 29 Boston University School of Public Health, Boston, MA, USA
96 30 Departments of Environmental Health and Epidemiology, Harvard TH Chan School of Public Health, Boston,
97 MA, USA
98 31 German Center for Diabetes Research (DZD), München-Neuherberg, Ingolstädter Landstr. 1, 85764,
99 Neuherberg, Germany
100 32 Institute of Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-University,
101 Munich, Germany
102 33 Geriatric Unit, Azienda Sanitaria Firenze (ASF), Florence, Italy
103 34 Network Aging Research (NAR), Univ of Heidelberg, Heidelberg, Germany
104 35 Precision Medicine Program, Department of Environmental Health Sciences, Mailman School of Public
105 Health, Columbia University, New York, NY, USA
106 36 Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, USA

107
108 † Authors contribute equally

109 * Corresponding authors

110
111 Daniel Levy, MD
112 Framingham Heart Study
113 Population Sciences Branch
114 National Heart, Lung, and Blood Institute
115 73 Mt. Wayte Avenue, Suite 2
116 Framingham, MA 01702
117 Email : LevyD@nih.gov
118 Phone: 508-935-3458
119 Fax: 508-872-2678

120
121 James S. Pankow, PhD, MPH
122 Division of Epidemiology and Community Health
123 School of Public Health, University of Minnesota
124 Minneapolis, MN 55455
125 Email: panko001@umn.edu

126
127 Tianxiao Huan, PhD
128 Framingham Heart Study

129 National Heart, Lung, and Blood Institute
130 Framingham, MA 01702
131 Email: tianxiao.huan@umassmed.edu
132

133 **Running title:** Epigenetic prediction of mortality

134

135 **Checklist:**

136 (1) total character count; **47,195**

137 (2) word count of the Summary; **247**

138 (3) the number of papers cited in the References; **52**

139 (4) a listing of all Tables (Table 1, Table 2, etc.);

140 **Table 1: Clinical characteristics the 15,013 study participants.**

141 **Table 2: Trans-ethnic replicated all-cause mortality related CpGs.**

142 **Table 3: Performance robustness comparison of mortality predictors in FHS and ARIC cohorts.**

143 (5) a listing of all Figures (Fig. 1, Fig. 2, etc.) including, (a) whether the Figure should be in colour,
144 greyscale or black and white, (b) whether the Figure should appear in 1-column or 2-column format,
145 (c) the size of the Figure at full scale (mm x mm), (d) the smallest font size used in the Figure at full
146 scale.

Figure No	Color	Greyscale	Black and white	Single	Double	Size	Smallest font size used in the figure at full scale
Figure 1			Yes		Yes	80 mm	12
Figure 2			Yes	Yes		80 mm	12
Figure 3			Yes	Yes		80 mm	12

147

148 **Abstract**

149 DNA methylation (DNAm) has been reported to be associated with many diseases and mortality. We
150 hypothesized that the integration of DNAm with clinical risk factors would improve mortality
151 prediction. We performed an epigenome-wide association study of whole blood DNAm in relation to
152 mortality in 15 cohorts (n=15,013). During a mean follow-up of 10 years, there were 4314 deaths
153 from all-causes including 1235 cardiovascular disease (CVD) deaths and 868 cancer deaths. Ancestry-
154 stratified meta-analysis of all-cause mortality identified 163 CpGs in European ancestry (EA) and 17
155 in African ancestry (AA) participants at $P < 1 \times 10^{-7}$, of which 41 (EA) and 16 (AA) were also
156 associated with CVD death, and 15 (EA) and 9 (AA) with cancer death. We built DNAm-based
157 prediction models for all-cause mortality that predicted mortality risk independent of clinical risk
158 factors. The mortality prediction model trained by integrating DNAm with clinical risk factors
159 showed a substantial improvement in prediction of cancer death with 11% and 5% increase in the C-
160 index in internal and external replications, compared with the model trained by clinical risk factors
161 alone. Mendelian randomization identified 15 CpGs in relation to longevity, CVD, or cancer risk. For
162 example, cg06885782 (in *KCNQ4*) was positively associated with risk for prostate cancer (Beta=1.2,
163 $P_{MR}=4.1 \times 10^{-4}$), and negatively associated with longevity (Beta=-1.9, $P_{MR}=0.02$). Pathway analysis
164 revealed that genes associated with mortality-related CpGs are enriched for immune and cancer
165 related pathways. We identified replicable DNAm signatures of mortality and demonstrated the
166 potential utility of CpGs as informative biomarkers for prediction of mortality risk.

167

168 **Key words:** DNA methylation; machine learning; mortality; cardiovascular disease; cancer

169

170 **Introduction**

171 Despite substantial evidence of heritability of human longevity ($h^2 = 10\text{-}30\%$), genome-wide
172 association studies (GWAS) have reported few loci associated with human longevity (Deelen et al.,
173 2019; Pilling et al., 2017; Timmers et al., 2019; van den Berg, Beekman, Smith, Janssens, &
174 Slagboom, 2017). DNA methylation (DNAm), the covalent binding of a methyl group to the 5'
175 carbon of cytosine-phosphate-guanine (CpG) dinucleotide sequences, reflects a wide range of
176 environmental exposures and genetic influences at the molecular level and altered DNAm has been
177 shown to regulate gene expression (Jones & Takai, 2001). Recent studies have reported DNAm
178 patterns associated with age in humans (Hannum et al., 2013; Horvath, 2013; Levine et al., 2018; Lu
179 et al., 2019). Estimates of biological age based on DNAm, referred to as "epigenetic age" or "DNAm
180 age" have been validated in numerous studies, although the functions of these age-associated CpGs
181 are largely unknown (Horvath et al., 2015; Lu et al., 2019; Marioni, Shah, McRae, Chen, et al., 2015;
182 Marioni, Shah, McRae, Ritchie, et al., 2015). DNAm age also has been shown to be predictive of
183 many age-related diseases and of all-cause mortality (Chen et al., 2016; Dugué et al., 2018; Levine et
184 al., 2018; Lu et al., 2019; Marioni, Shah, McRae, Chen, et al., 2015).

185 Despite the association of DNAm age with a variety of age-associated outcomes, age-related CpGs
186 are different from those that are most strongly associated with mortality. Relatively few DNAm
187 studies have focused on mortality as the primary outcome (Colicino et al., 2020; Svane et al., 2018;
188 Zhang et al., 2017). Moreover, due to sample size limitations, most DNAm mortality studies have not
189 typically investigated cause-specific mortality such as death due to cardiovascular disease (CVD) and
190 cancer. Additionally, little is known about the prediction performance of DNAm-based mortality
191 models and whether or not such approaches improve mortality prediction above and beyond
192 established clinical risk factors.

193 We hypothesized that inter-individual variation in DNAm is associated with all-cause mortality risk
194 and with cause-specific mortality, and that we could build models incorporating CpGs that would
195 improve mortality prediction beyond established clinical risk factors. In this study, we report the

196 results of a meta-analysis of epigenome-wide association studies (EWAS) of all-cause mortality and
197 cause-specific mortality including death from CVD and cancer in up to 15,013 individuals from 15
198 prospective cohort studies in which DNAm was measured in whole blood. We built all-cause
199 mortality risk prediction models using penalized regression and machine learning methods and
200 integrated DNAm and established mortality clinical risk factors and validated the models'
201 performance. Additionally, using Mendelian randomization, we identified putatively causal CpGs for
202 mortality. Last, we investigated the downstream gene expression and pathway changes of the
203 mortality-related CpGs by testing associations between DNAm and gene expression. **Fig. S1**
204 summarizes the multi-step study design.

205

206 **Results**

207 **Study population**

208 **Table 1** presents the major clinical characteristics of the 15,013 study participants including 11,684
209 European ancestry (EA, mean age 65, 55% women) and 3329 African ancestry (AA, mean age 59, 70%
210 women) participants from 15 cohorts (**Table S1** summarizes additional clinical characteristics). Most
211 studies had fewer than 15 years of mean follow-up (mean values ranged from 6.4 to 13.7 years),
212 except ARIC (mean follow-up of 20.0 years in ARIC EA and 18.6 in ARIC AA participants,
213 respectively). During follow-up of EA participants, 2907 died of any cause, 688 of CVD, and 546 of
214 cancer; among AA participants, 1407 died of any cause, 547 of CVD, and 322 of cancer.

215 **Ancestry-stratified epigenome-wide meta-analysis of all-cause mortality**

216 At Bonferroni-corrected $P < 1 \times 10^{-7}$ ($\sim 0.05/400,000$), we identified 163 CpGs whose differential
217 methylation in whole blood was associated with all-cause mortality in EA participants, and 17 CpGs
218 in AA participants, after adjustment of age, sex, lifestyle factors, clinical risk factors, white blood cell
219 types, and technical covariates. **Tables S2-S3** present the results for all CpGs at $P < 1 \times 10^{-5}$. Overall
220 genomic inflation in meta-analysis (λ) was estimated at 1.15 or less, indicating low inflation and low

221 risk of false-positive findings. Even though cohort-specific analysis showed slightly higher genomic
222 inflation in some cohorts ($\lambda > 1.5$ in two cohorts, **Table S4**), forest plots show that the results were not
223 driven by results from one or several cohorts (**Fig. S2**). Sensitivity analysis results including meta-
224 analysis after correcting for λ in each cohort, meta-analysis after excluding results from two cohorts
225 with $\lambda > 1.5$ and meta-analysis after excluding RS cohort are included in **Table S5-S6**. Results of the
226 sensitivity analysis remained consistent with the main results in terms of direction and effect estimates
227 with Pearson's correlation $r = 0.99$ (in EA, corrected for λ in each cohorts), $r = 1.00$ (in EA, after
228 removing two cohorts with $\lambda > 1.5$), $r = 1.00$ (in EA, after removing RS) and $r = 1.00$ (in AA, corrected
229 for λ in each cohorts).

230 Among the 177 all-cause mortality-related CpGs (union set of EA and AA results at $P < 1 \times 10^{-7}$), the
231 vast majority of significant CpGs (151, 85%) were inversely associated with mortality, with hazards
232 ratios (HRs) < 1 (range 0.72 to 0.89 per standard deviation [SD]). Methylation at the remaining 26
233 (15%) CpGs was positively associated with mortality, with HRs > 1 (range 1.13 to 1.32). The 177
234 CpGs are annotated to 121 genes and 43 intergenic regions.

235 **Transethnic replication and sensitivity analysis**

236 Of the 163 all-cause mortality related CpGs in EA participants, 18 (11%) had $P < 0.0003$ (0.05/163) in
237 AA participants; of the 17 CpGs in AA participants, 12 (71%) had $P < 0.004$ (0.05/17) in EA
238 participants. **Table 2** displays the transethnic replicated CpGs including 27 unique CpGs. The top 3
239 transethnic replicated CpGs in EA participants remained the top 3 in AA participants, including
240 cg16743273 for *MOBK2A*, cg18181703 for *SOCS3*, and cg21393163 at an intergenic region (Chr.1:
241 12217629).

242 Because ARIC had longer follow-up than the other cohorts, in sensitivity analysis, we truncated ARIC
243 follow up at 15 years. The HRs for the significant CpGs (at $P < 1 \times 10^{-5}$) remained consistent with the
244 main results in terms of direction and effect estimates with Pearson's correlation $r = 1.00$ and $r = 0.99$
245 in EA and AA participants, respectively (**Table S2-S3** and **Fig. S3**).

246 **Associations of DNAm with CVD death and cancer death**

247 In comparison with results for all-cause mortality, fewer CpGs were associated with CVD death (at
248 $P < 1 \times 10^{-7}$, $n=4$ in EA, and $n=15$ in AA) and cancer death ($n=0$ in EA, and $n=1$ in AA) **Tables S7-S8**
249 report the corresponding results at $P < 1 \times 10^{-5}$. Among the 163 all-cause mortality-related CpGs
250 identified in EA participants at $P < 1 \times 10^{-7}$, 41 CpGs were associated with CVD death, 16 with cancer
251 death, and 5 with both (at $P < 0.05/163$, **Table S2**). Among the 17 CpGs identified in AA participants
252 at $P < 1 \times 10^{-7}$, 15 were associated with CVD death, 9 with cancer death, and 8 with both (at $P < 0.05/17$,
253 **Table S3**). **Fig. 1** shows the effect sizes and direction of effect for the top CpGs associated with all-
254 cause mortality, and their consistency with the results of analyses of CVD death and cancer death. We
255 found that if a CpG was positively correlated with all-cause mortality, then it also was positively
256 correlated with CVD death and cancer death, and vice versa.

257 **Mortality prediction model**

258 To investigate if DNAm can be used to predict mortality risk, we constructed prediction models for
259 all-cause mortality, and evaluated their prediction of all-cause mortality, CVD death, and cancer death.
260 To ensure unbiased validation, we split the EA cohorts into separate discovery and replication sets
261 (**Fig. S1** shows the analysis flowchart). The discovery cohorts consisted of 8288 participants
262 (including 2173 deaths from all-causes) from 10 cohorts, excluding FHS ($n=2427$) and ARIC ($n=969$),
263 which were used as replication cohorts. The meta-analysis of the discovery set identified 74 CpGs at
264 $P < 1 \times 10^{-7}$, 158 CpGs at $P < 1 \times 10^{-6}$, 357 CpGs at $P < 1 \times 10^{-5}$, 931 CpGs at $P < 1 \times 10^{-4}$, 2717 CpGs at
265 $P < 1 \times 10^{-3}$, and 28,323 CpGs at $P < 0.05$. We evaluated three types of input features: a) clinical risk
266 factors only (i.e., clinical risk factor models); b) CpGs identified in the meta-analysis of the discovery
267 set (i.e., CpG models); and c) the input features including both CpGs and clinical risk factors (i.e.,
268 integrative models). We also compared four prediction methods including Elastic net - Cox
269 proportional hazards (Elastic-coxph) (Friedman, Hastie, & Tibshirani, 2010), Random survival forest
270 (RSF) (Ishwaran, Kogalur, Blackstone, & Lauer, 2008), Cox-nnet (Ching, Zhu, & Garmire, 2018),
271 and DeepSurv (Katzman et al., 2018) (see Methods for details). In general, the four prediction
272 methods did not show major differences in predicting mortality outcomes as assessed by multiple

273 evaluation metrics (**Table S9** lists the evaluation metrics across all four methods). To simplify the
274 presentation of results, we focused on the Elastic-coxph method.

275 *Clinical risk factors strongly predict all-cause mortality and CVD death:* The C-index of the clinical
276 risk factor models (age, sex, and 12 clinical risk factors) was 0.80 for all-cause mortality, 0.81 for
277 CVD death, and 0.77 for cancer death in FHS (reflecting the average values of 10-fold cross-
278 validation). Among the 12 clinical risk factors, prevalent cancer status was the major contributor to
279 predicting cancer death. After excluding individuals with prevalent cancer at the time of blood draw
280 for DNAm measurements (i.e., the start of follow up), the C-index of the clinical risk factor model
281 was 0.57 for cancer death. Finally, two clinical risk models were built using the optimum parameters
282 selecting by cross-validation (see Methods). The first one was trained using all FHS participants and
283 included 10 risk factors selected by the Elastic-coxph method (to predict all-cause mortality and CVD
284 death, **Table S10**), and the second was trained using FHS participants excluding those with prevalent
285 cancer cases and including 10 risk factors (to predict cancer death, **Table S11**). The corresponding C-
286 index of the clinical risk factor model was 0.75 for all-cause mortality (HR=2.64 per SD in the risk
287 score, 95% CI [2.21, 3.15], $P=4.4 \times 10^{-27}$), 0.81 for CVD death (HR=3.51, 95% CI [2.58, 4.79], $P=2.1$
288 $\times 10^{-15}$), and 0.71 for cancer death (excluding prevalent cancer samples, HR=2.35, 95% CI [1.74, 3.18],
289 $P=2.3 \times 10^{-8}$) in ARIC EA participants with follow up truncated at 15 years (**Table 3**).

290 *DNAm predicts mortality independently of age and clinical risk factors:* The models using all-cause
291 mortality-related CpGs identified in the discovery cohorts as the sole input feature (the CpG model)
292 were predictive of all-cause mortality, CVD death, and cancer death in the replication set. As shown
293 in **Fig. S4**, when more discovery CpGs were added to the model, the prediction performance metrics
294 did not always improve. In FHS, the models with discovery CpGs at $P < 1 \times 10^{-3}$ showed the best
295 predictive performance for all-cause mortality (C-index =0.77) and CVD death (C-index =0.82), but
296 the model with discovery CpGs at $P < 1 \times 10^{-5}$ showed the best predictive performance for cancer death
297 (excluding prevalent cancer cases, [C-index =0.65]). The final CpG models that were trained using all
298 FHS participants are provided in **Table S12** including 76 CpGs to predict all-cause mortality and
299 CVD death, and in **Table S13** including 56 CpGs to predict cancer death (excluding prevalent cancer

300 cases). The C-index of the CpG models with the best predictive performance in ARIC were 0.72 for
301 all-cause mortality (HR=2.21, 95% CI [1.86, 2.62], $P=2.0 \times 10^{-20}$), 0.77 for CVD death (HR=2.62, 95%
302 CI [1.96, 3.51], $P=9.9 \times 10^{-11}$) and 0.73 for cancer death (HR=2.22, 95% CI [1.67, 2.95], $P=3.2 \times 10^{-8}$,
303 **Table 3**). The association of the mortality risk scores calculated by the CpG models with mortality
304 outcomes remained significant after adjusting for age, sex, and clinical risk factors; for all-cause
305 mortality (HR=1.68, 95% CI [1.37, 2.07], $P=9.8 \times 10^{-7}$), CVD death (HR=1.81, 95% CI [1.24, 2.64],
306 $P=0.002$), and cancer death (HR=2.04, 95% CI [1.46, 2.86], $P=3.0 \times 10^{-5}$).

307 *The integrative model (trained by CpGs and clinical risk factors) moderately improved upon the*
308 *clinical risk factor model for all-cause mortality and CVD death, and greatly improved the prediction*
309 *of cancer death: As shown in Table 3, the integrative models demonstrated robustness for predicting*
310 *mortality outcomes, with a good C-index, HR, and low brier error rate. The final integrative models*
311 *trained using data from all FHS participants are provided in Table S14 including nine clinical risk*
312 *factors and 36 CpGs to predict all-cause mortality and CVD death, and in Table S15 including seven*
313 *clinical risk factors and 42 CpGs to predict cancer death (excluding prevalent cancer cases). The C-*
314 *index values of the integrative models were 0.80 (FHS, reflecting the average values of 10-fold cross-*
315 *validation) and 0.77 (ARIC) for all-cause mortality; 0.83 (FHS) and 0.80 (ARIC) for CVD death; and*
316 *0.69 (FHS) and 0.76 (ARIC) for cancer death. Kaplan-Meier survival curves for the mortality risk*
317 *scores (split into high, middle, and low risk groups) in the ARIC EA cohort (computed by the*
318 *integrative models using clinical risk factors and CpGs at discovery $P < 1 \times 10^{-6}$, Table S14-S15)*
319 *illustrates the higher death rate for those with a higher mortality risk score (log-rank $P < 1 \times 10^{-6}$, Fig. 3).*
320 In comparison to the clinical risk factor models, the integrative models moderately improved
321 prediction of all-cause mortality (0.7% increase in C-index with addition of CpGs in FHS and 2%
322 increase in ARIC), and of CVD death (2% increase in C-index in FHS, but no increase in ARIC). We
323 speculate that the reason for this minor increase is because the mortality-related CpGs capture the
324 contributions of clinical risk factors for CVD death. For cancer death, the C-index of the integrative
325 model revealed an 11% increase in FHS above and beyond the clinical risk factor model and a
326 corresponding 5% increase in ARIC.

327 We also tested the mortality prediction models' performance using the entire ARIC EA data (without
328 truncation, **Table S16**). Due to the long follow-up time in this older cohort (mean age 59.8 at baseline,
329 with 20 ± 5.5 years follow-up), the integrative model exhibits very similar performance features as the
330 model using age and sex as the sole input features for predicting all-cause mortality and CVD death.
331 The integrative model improved prediction of cancer death with 2% increase in the C-index versus the
332 clinical risk factor model.

333 We further tested all-cause mortality prediction models in the CARDIA study (baseline age 45 ± 3
334 years). The CARDIA study has 12 years of follow-up, during which there were 27 deaths from all
335 causes in 905 participants with DNA methylation. As shown in **Table S17**, the clinical risk factor
336 model, the CpG model, and the integrative model each predicted all-cause mortality, and each
337 outperformed the DNAm age models.

338 **Comparing the mortality prediction model with DNAm age**

339 We compared four DNAm age models (i.e., PhenoAge (Levine et al., 2018), Horvath Age (Horvath,
340 2013), Hannum Age (Hannum et al., 2013), and GrimAge (Lu et al., 2019)) with our mortality
341 prediction models (CpG only models and integrative CpG plus 12 risk factor models) for all-cause
342 mortality, CVD death, and cancer death in ARIC participants. The associations of mortality risk
343 scores calculated by mortality prediction models with mortality outcomes were statistically significant,
344 and the associations remained significant after adjusting for age and sex, and after additionally
345 adjusting for the clinical risk factors. The four DNAm age models were significantly associated with
346 mortality outcomes. After adjusting for age, sex and clinical risk factors, however, only GrimAge
347 remained associated with all-cause mortality, CVD death, and cancer death. None of the other three
348 DNAm age predictors was associated with mortality outcomes after additionally adjusting for clinical
349 risk factors (**Fig. 3**). The mortality prediction models (both the CpG only model and the integrative
350 model that included the clinical risk factors and CpGs) outperformed the GrimAge model in
351 prediction of mortality outcomes in terms of HRs and P values. The associations of mortality risk
352 scores with mortality outcomes remain significant after adjusting for the four DNAm age (**Table S18**).

353 **Associations of DNAm with genetic variants and Mendelian randomization analysis**

354 Among the 177 all-cause mortality-related CpGs (union of EA and AA results at $P < 1 \times 10^{-7}$), 123
355 CpGs had significant associations with genetic variants (i.e. *cis*- or *trans*-meQTL variants). meQTL
356 variants for 80 CpGs could be linked to 618 GWAS Catalog(Buniello et al., 2019) index SNPs
357 associated with 432 complex traits or diseases (**Table S18**).

358 We further performed multiple instrumental variable (IV) MR analysis for the 17 CpGs having ≥ 3
359 independent *cis*-meQTL SNPs (pruned by LD $r^2 < 0.01$, as IVs, to model the causal relations of
360 differential methylation at these CpGs (as the exposure) on the various outcomes, including longevity
361 (Deelen et al., 2019), CVD, CVD risk factors, and cancer (Evangelou et al., 2018; Locke et al., 2015;
362 Michailidou et al., 2017; Phelan et al., 2017; Schumacher et al., 2018; Scott et al., 2017; Wang et al.,
363 2014; Willer et al., 2013). At $P_{MR} < 0.05$, MR supported causal effects of 15 CpGs on one or more
364 outcome (**Table S19**), and 4 CpGs were statistically significant at $P_{MR} < 0.05/17$, including
365 cg06885782 (within 1500 bases upstream of transcription start site [TSS1500] of *KCNQ4*) and
366 cg04907244 (TSS1500 of *SNORD93*) in relation to prostate cancer (Schumacher et al., 2018)
367 (Beta=1.2 and 2.1; and $P_{MR} = 4.1 \times 10^{-4}$ and 0.003, respectively), cg07094298 (in the gene body of
368 *TNIP2*) in relation to lung cancer (Wang et al., 2014) (Beta =2.2, and $P_{MR} = 0.003$), and cg18241337
369 (in the gene body of *SSR3*) in relation to total cholesterol (Willer et al., 2013) (Beta=0.5, and
370 $P_{MR} = 0.003$). cg06885782 (*KCNQ4*) also was associated with longevity (Deelen et al., 2019) (Beta=-
371 1.9, $P_{MR} = 0.02$).

372 **Associations of DNAm with gene expression, and pathway analysis**

373 For the 177 all-cause mortality-related CpGs at $P < 1 \times 10^{-7}$, we assessed associations of CpGs with
374 nearby gene expression (i.e. *cis* gene expression; within +/- 1 Mb) and identified 15 *cis*- DNAm-
375 mRNA associated pairs (13 CpGs and 15 mRNAs) at $P < 3 \times 10^{-10}$. The genes located at these CpGs or
376 *cis*-eQTM mRNAs were not enriched for any biological processes or pathways. For the 719 all-cause
377 mortality-related CpGs at $P < 1 \times 10^{-5}$, 495 genes located at CpG sites were enriched for positive
378 regulation of transcription from RNA polymerase II promoter (Gene Ontology [GO] (Ashburner et al.,

379 2000), fold change = 1.9, FDR=0.05), and pathways for cancer (Kyoto Encyclopedia of Genes and
380 Genomes [KEGG] pathway (Kanehisa & Goto, 2000), fold change =2.2, FDR=0.13, **Table S20**).
381 There were 79 *cis*-DNAm-mRNA pairs (63 CpGs and 67 mRNAs, **Table S21**). The 67 *cis*-eQTM
382 mRNAs were enriched for multiple immune functions including immune response (GO, fold change =
383 6.3, FDR=0.01).

384

385 **Discussion**

386 By performing EWAS using whole blood derived DNA from 15,013 individuals from 15 cohorts with
387 the accrual of 4314 deaths during a mean follow up of more than 10 years, we identified robust
388 DNAm signatures of all-cause and cause-specific mortality. We developed replicable mortality
389 predictors by integrating mortality-related CpGs with traditional clinical risk factors. The integrative
390 models that included clinical risk factors and CpGs showed modest improvement in prediction of all-
391 cause mortality and CVD death, and a substantial improvement in prediction of cancer death
392 compared to the traditional risk factor model in the FHS (internal cross-replication) and ARIC
393 (external independent replication) cohorts.

394 Our study is one of the largest EWAS of mortality to date (Colicino et al., 2020; Svane et al., 2018;
395 Zhang et al., 2017) and it revealed many replicable DNAm signatures for all-cause mortality. Our
396 results are consistent with those from previous EWAS of all-cause mortality; the vast majority of
397 CpGs (85% in our study, 84% in (Zhang et al., 2017), and 67 % in (Colicino et al., 2020)) were
398 inversely associated with mortality suggesting a greater mortality risk with lower CpG methylation.
399 Our study identified more CpGs in EA cohorts (n=163) than in AA cohorts (n=17). As shown in
400 **Table 2**, the effect sizes (i.e., HR) of mortality-related CpGs in EA and AA participants were quite
401 similar. We speculate that our study identified many more CpGs in EA participants than AA
402 participants due the greater statistical power of the larger EA sample size. Using different DNAm data
403 normalization methods (such as Noob (Triche Jr, Weisenberger, Van Den Berg, Laird, & Siegmund,
404 2013), SWAN (Maksimovic, Gordon, & Oshlack, 2012), BMIQ(Teschendorff et al., 2013), and

405 Dasen (Pidsley et al., 2013), see **Additional File 1**) in different cohorts may also affect the
406 reproducibility of the results. Among the top mortality-associated CpGs, many were associated with
407 common traits associated with diseases in prior EWAS including BMI (e.g., cg03725309 in *SARS*)
408 (Mendelson et al., 2017), smoking (e.g., cg05575921 in *AHRR*) (Joehanes et al., 2016), blood pressure
409 (e.g., cg03068497 and cg21429551 in *GARS*) (Richard et al., 2017), alcohol consumption (e.g.,
410 cg02583484 in *HNRNPA1*) (Liu et al., 2018), and diet (e.g., cg18181703 in *SOCS3*) (Ma et al., 2020).
411 Among the 177 all-cause mortality-related CpGs (union of EA and AA results at $P < 1 \times 10^{-7}$), 123
412 CpGs had significant associations with genetic variants (i.e., *cis*- or *trans*-meQTL variants identified
413 previously (Huan et al., 2019)). For the remaining 44 CpGs, however, this does not mean that their
414 methylation levels have nothing to do with genetic variation. It is possible that the previous meQTL
415 study lacked sufficient statistical power to identify meQTLs for those CpGs. The mortality-related
416 CpGs are linked to hundreds of human complex diseases/traits via their *cis*-meQTL SNPs, which
417 coincide with 618 GWAS Catalog (Buniello et al., 2019) index SNPs. This leads us to hypothesize
418 that many disease/phenotype associated SNPs may contribute to disease processes via effects on
419 mortality-related CpGs. In this way, the mortality-related CpGs may contribute causally to disease. To
420 test this hypothesis, we conducted MR analyses that confirmed several putatively causal associations
421 of mortality-related CpGs with longevity (Deelen et al., 2019), CVD (Nikpay et al., 2015), CVD risk
422 factors, and several types of cancer (Evangelou et al., 2018; Locke et al., 2015; Michailidou et al.,
423 2017; Phelan et al., 2017; Schumacher et al., 2018; Scott et al., 2017; Wang et al., 2014; Willer et al.,
424 2013) (**Table S19**). Among the four CpGs passing a Bonferroni-corrected threshold in MR analyses,
425 cg06885782 in *KCNQ4* was reported to be associated with risk for prostate cancer ($\beta = 1.2$,
426 $P_{MR} = 4.1 \times 10^{-4}$), and negatively associated with longevity ($\beta = -1.9$, $P_{MR} = 0.02$). *KCNQ4* (potassium
427 voltage-gated channel subfamily Q member 4) was previously reported to be associated with age-
428 related hearing impairment (Van Eyken et al., 2006), and it contains genetic variants associated with
429 all-cause mortality and survival free of major diseases (Walter et al., 2011). cg07094298 in the gene
430 body of *TNIP2* was previously identified as causal for lung cancer. A recent study reported *TNIP2*-
431 *ALK* fusion in lung adenocarcinoma (Feng et al., 2019). cg04907244 (in TSS1500 of *SNORD93*) was

432 identified as causal for prostate cancer by MR. *SNORD93* and its methylation was reported to be
433 associated with several cancer types including uveal melanoma (Gong et al., 2017), breast cancer
434 (Patterson et al., 2017), and renal clear cell carcinoma (Zhao et al., 2020). Pathway analysis further
435 supported a role of mortality-related CpGs in relation to cancer risk. The intragenic CpGs were
436 enriched for genes in cancer pathways, possibly as a consequence of the expression of nearby genes
437 (*cis*-eQTM analysis, **Table S21**) related to immune function.

438 The 14 clinical risk factors for mortality were chosen based on prior knowledge. In contrast, there are
439 far fewer established risk factors for cancer death other than age, sex, BMI, smoking, and alcohol
440 consumption. It is not a surprise that the clinical risk factors themselves accurately predicted all-cause
441 mortality (C-index = 0.80 in FHS, and 0.75 in ARIC) and CVD death (0.81 in FHS and 0.81 in ARIC),
442 but not cancer death (0.57 in FHS and 0.71 in ARIC). Even though the clinical risk factors are
443 important for stratifying CVD risk, clinical risk factors themselves are unable to reveal molecular
444 mechanism and are thereby unable to highlight causal mechanisms or promising therapeutic targets.
445 After integrating clinical risk factors with DNAm in the all-cause mortality prediction model, the C-
446 index only slightly increased (less than 2%) compared with the clinical risk factors model with regard
447 to all-cause mortality and CVD death. As shown in **Table S14**, nine of the 14 clinical risk factors,
448 including age, sex, physical activity, prevalent cancer, type II diabetes, hypertension, CHD, heart
449 failure and stroke, as well as 36 CpGs that were selected as the representative features. Compared
450 with clinical risk factors, the individual coefficients of the CpGs are much smaller. The small increase
451 in the C-index and the small coefficients of the CpGs suggest that the contribution of CpGs to the
452 prediction of death may overlap with these clinical risk factors. We also found that the mortality-
453 related CpGs as the sole input features were still able to predict mortality outcomes after adjusting for
454 clinical risk factors. This suggests that mortality-related CpGs may identify novel molecular
455 mechanisms contributing to CVD mortality that cannot be captured by existing clinical risk factors.

456 In contrast to CVD and CVD mortality, for which established risk factors are highly predictive of risk,
457 the prediction of cancer and cancer mortality has proved much more challenging. Owing to the lower
458 prediction using clinical risk factors alone (0.57 in FHS and 0.71 in ARIC), the mortality-related

459 CpGs improved risk prediction of cancer death over and above the clinical risk factor model with an
460 11% increase in the C-index in FHS and a 5% increase in ARIC. We further tested whether the all-
461 cause mortality prediction model can be used to predict mortality among all participants in the FHS
462 with prevalent cancer (n=389). During a mean follow up of 9 years, there were 165 deaths in this
463 group. The integrative mortality model predicted mortality risk among cancer cases (HR [95%CI]:
464 4.23 [2.63-6.80], $P = 2.9 \times 10^{-9}$). These results in conjunction with MR and pathway analysis, show
465 strong evidence of potential causal relations between mortality-related CpGs and pathways in cancer.
466 Based on these results, we hypothesize that mortality-related CpGs can shed light on the epigenetic
467 regulation of molecular interactions and help to identify novel therapeutic targets to reduce mortality
468 risk for both CVD and cancer death.

469 Recent studies have used DNAm of multiple CpG sites to predict chronological age (i.e. DNAm age),
470 and showed that DNAm age was associated with all-cause mortality. We explored the prediction
471 provided by these DNAm age models and show that PhenoAge (Levine et al., 2018), Horvath Age
472 (Horvath, 2013), Hannum Age (Hannum et al., 2013), and GrimAge (Lu et al., 2019) were associated
473 with mortality before accounting for risk factors. Only GrimAge, however, remained associated with
474 mortality after adjusting for clinical risk factors. In contrast, the other three DNAm age models were
475 no longer associated with mortality (**Fig. 3**). One possible explanation is that the three DNAm age
476 predictors (i.e., PhenoAge, Horvath Age, and Hannum Age) identify CpGs associated with age, but
477 are not specific for all-cause or cause-specific mortality risk. Of note, the CpGs that serve as DNAm
478 mortality predictors and those that predict DNAm age in the three models do not overlap. Among the
479 top CpGs (N=177) associated with all-cause mortality in our EWAS, only cg00687674 in *TMEM84* is
480 included in PhenoAge (Levine et al., 2018), and only cg19935065 in *DNTT* appears in Hannum Age
481 (Hannum et al., 2013). GrimAge may have outperformed the other three DNAm age models in
482 predicting mortality because the CpGs that it uses are associated with the levels of 80 CVD-related
483 blood proteins, and with lifestyle and clinical risk factors (such as smoking), and mortality (Ho et al.,
484 2018; Shah et al., 2019; Yao et al., 2018). However, because the CpGs in the GrimAge model are not
485 disclosed (i.e. they are proprietary), we were unable to determine if any of the mortality-related CpGs

486 in our study overlap with CpGs in the GrimAge model. Of note, our mortality prediction models (both
487 the CpG only model and the integrative model that included CpGs and the clinical risk factors)
488 outperformed GrimAge in prediction of mortality outcomes.

489 We tested and compared four prediction methods including Elastic-coxph (Friedman et al., 2010), a
490 regression based method, and three machine learning methods (Ching et al., 2018; Ishwaran et al.,
491 2008; Katzman et al., 2018). The machine learning models did not outperform Elastic-coxph (**Table**
492 **S9** and **Fig. S3**). The clinical risk factor model trained by machine learning methods did not perform
493 well in independent external replication. For example, the C-index of the clinical risk factor model for
494 all-cause mortality was 0.67 using RSF¹⁷ versus 0.75 using Elastic-coxph in ARIC participants. Based
495 on this metric, the machine learning methods did not outperform the regression-based methods when
496 there were relatively few features as inputs.

497 The primary outcome of our study was all-cause mortality. We did not train prediction models for
498 CVD death or cancer death, but we tested the prediction ability of the all-cause mortality predictor on
499 CVD death and cancer death. The CpGs in the model were restricted to all-cause mortality related
500 CpGs. As shown in **Fig. 1**, the top DNAm signatures for all-cause mortality showed the same
501 direction of effect for CVD death and cancer death. It is possible that some CpGs show opposite
502 directions in relation to CVD death and cancer death, but we did not train separate models for these
503 outcomes. Therefore, developing separate prediction models for CVD death and cancer death with a
504 very large sample size would be an important next step.

505

506 **Conclusions**

507 In conclusion, the ancestry-stratified epigenome-wide meta-analyses in 15 population-based cohorts
508 identified replicable DNAm signatures of all-cause and cause-specific mortality. The top mortality-
509 associated CpGs were linked with genes involved in immune and cancer related pathways, and were
510 reported to be associated with human longevity, CVD risk factors, and several types of cancer. We

511 constructed and validated DNAm-based prediction models that predicted mortality risk independent
512 of established clinical risk factors. The prediction model trained by integrating DNAm with clinical
513 risk factors showed modest improvement in prediction of all-cause mortality and CVD death, and a
514 substantial improvement in prediction of cancer death, compared with the model trained by clinical
515 risk factors alone. The mortality-related CpG sites, and the DNAm-based prediction models may
516 serve as useful clinical tools for assessing all-cause and cause-specific mortality risk and for
517 developing new therapeutic strategies.

518

519 **Methods**

520 **Study population**

521 This study included 15,013 participants from 15 population-based cohorts. There were 11,684
522 European ancestry (EA) participants from 12 cohorts, including the Atherosclerosis Risk in
523 Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Danish Twin Register
524 sample (DTR), the Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und
525 optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung (ESTHER), the
526 Framingham Heart Study (FHS), the Invecchiare in Chianti (InCHIANTI) Study, the Cooperative
527 Health Research in the Region of Augsburg (KORA F4), the Lothian Birth Cohorts of 1921
528 (LBC1921) and 1936 (LBC1936), the Normative Aging Study (NAS), the Rotterdam Study (RS), and
529 Women's Health Initiative (WHI); and 3329 Africa ancestry (AA) participants from 3 cohorts,
530 including ARIC, CHS, and WHI. For each participant, we calculated the follow-up time between the
531 date of the blood draw for DNAm measurements and the date at death or last follow up. Mean follow
532 up was less than 15 years (range 6.2 to 13.7) for most cohorts, except for ARIC (mean 20.0 for EA
533 and 18.6 for AA). The protocol for each study was approved by the institutional review board of each
534 cohort. Further details for each cohort were included in **Additional file1**.

535 **Mortality ascertainment and clinical phenotypes**

536 Outcomes including death from all causes, deaths from CVD, and deaths from cancer, were
537 prospectively ascertained in each cohort. Survival status and details of death were ascertained using
538 multiple strategies, including routine contact with participants for health history updates, surveillance
539 at the local hospital, review of obituaries in the local newspaper, and National Death Index queries.
540 Death certificates, hospital and nursing home records prior to death, and autopsy reports were
541 requested and reviewed. Date and cause of death were determined separately for each cohort
542 following review of all available medical records and /or were register-based.

543 The clinical and lifestyle risk factors (referred to as clinical risk factors for simplicity thereafter) used
544 as covariates in this study included age, sex, body mass index (BMI), smoking, alcohol consumption,
545 physical activity, educational attainment, and prevalent diseases including hypertension, coronary
546 heart disease (CHD), heart failure, stroke, type-II diabetes, and cancer. Fourteen clinical risk factors
547 were chosen based on prior knowledge; most of these are key CVD risk factors. The clinical risk
548 factors were ascertained at the time of blood draw for DNAm measurements. BMI was calculated as
549 weight (kg) divided by height squared (m²). Educational attainment (years of educational schooling),
550 physical activity (frequency, intensity or the metabolic equivalent of task [MET] scores), smoking
551 status (yes/no, or cigs/day), alcohol consumption (drinks per day) were self-reported or ascertained by
552 an administered questionnaire at routine research clinic visits. Diabetes was defined as a measured
553 fasting blood glucose level of >125 mg/dL or current use of glucose-lowering prescription medication.
554 Hypertension was defined as a measured systolic blood pressure (BP) ≥140 mm Hg or diastolic BP
555 ≥90 mm Hg or use of antihypertensive prescription medication. Cancer was defined as the occurrence
556 of any type of cancer excluding non-melanoma skin cancer.

557 **DNA methylation measurements and quality control**

558 For each cohort, DNA was extracted from whole blood and bisulfite-converted using a Zymo EZ
559 DNA methylation kit. DNAm was measured using the Illumina Infinium HumanMethylation450
560 (450K) BeadChip platform (Illumina Inc, San Diego, CA). Each cohort conducted independent

561 laboratory DNAm measurement, quality control (including sample-wise and probe-wise filtering, and
562 probe intensity background correction; see **Additional file1**).

563 **Cohort-specific epigenome-wide association analysis**

564 The correction of methylation data for technical covariates was cohort specific. Each cohort
565 performed an independent investigation to select an optimized set of technical covariates (e.g., batch,
566 plate, chip, row and column), using measured or imputed blood cell type fractions, surrogate variables,
567 and/or principal components. Most cohorts had previous publications using the same dataset for
568 EWAS of different traits, such as EWAS of alcohol drinking and smoking (Mendelson et al., 2017;
569 Michailidou et al., 2017). In this study, those cohorts used the same strategies as they did previously
570 for correcting for technical variables including batch (see **Additional file1**). To avoid false positives
571 driven by single CpG extreme values, in each cohort, we first performed rank-based inverse normal
572 transformation (INT) of DNAm β -values (the ratio of methylated probe intensity divided by the sum
573 of the methylation and unmethylated probe intensity). We then conducted time-to-event analyses
574 using Cox proportional hazards models to test for associations between each CpG and mortality
575 outcomes including all-cause mortality, CVD death, and cancer death using the *coxph()* function in
576 the ‘survival’ R library, adjusting for clinical risk factors (see **Mortality ascertainment and clinical**
577 **risk factors**), technical confounders, and familial relatedness. Because ARIC cohorts had much
578 longer follow-up than the other cohorts, ARIC follow up was truncated at 15 years and results were
579 compared to those before truncation to determine if results were impacted by duration of follow up.

580 In this study, we performed INT of DNAm β -values to avoid false positives driven by extreme values
581 of single CpGs. Using the FHS EWAS results as an example, **Table S21** shows that the top CpGs
582 associated with all-cause mortality (without INT) were no longer significant after performing INT.
583 This finding suggests that if we directly use DNAm β -values, those extreme outlier values could lead
584 to false positive results. Clearly, the distribution of DNA β -values is non-normal and for this reason,
585 we believe that the conservative INT approach we took protected against false positive results.

586 **Meta-analysis**

587 The meta-analysis was performed for all-cause mortality, CVD death, and cancer death in EA
588 (n=11,684) and AA (n=3329) participants respectively, using inverse variance-weighted random-
589 effects models implemented in *metagen()* function R packages
590 (<https://rdr.io/cran/meta/man/metagen.html>). We chose a random-effects model because of the
591 heterogeneity in follow-up length and population demographics in the different cohorts (**Table S1**).
592 We excluded the EWAS results for a study with <20 deaths. We excluded probes mapping to multiple
593 locations on the sex chromosomes or with an underlying SNP (MAF>5% in 1000 Genome Project
594 data) at the CpG site or within 10bp of the single base extension. In addition, the meta-analysis was
595 constrained to methylation probes passing filtering criteria in five or more cohorts (see **Additional**
596 **File1**), which resulted in ~400,000 CpGs that were included in the final analyses. The statistical
597 significance threshold was $P < 0.05/400,000 \approx 1 \times 10^{-7}$.

598 Three types of sensitivity analyses were performed including 1) correcting for λ values in each
599 cohorts (Devlin, Roeder, & Wasserman, 2001), 2) excluding two cohorts with $\lambda > 1.5$ from the meta-
600 analysis, and 3) excluding results of RS, because the cohort-specific analysis in RS having a strange
601 distribution of top hits. There were 157 CpGs identified at $P < 1e-7$ in the RS cohort-specific analysis.
602 The number is much more than the number of all-cause mortality associated CpGs identified in the
603 other cohorts.

604 **Mortality prediction models**

605 Mortality prediction models based on clinical risk factors and with the addition of DNAm were built
606 and tested in EA cohorts. The analysis flowchart is shown in **Fig. S1**. To ensure unbiased validation,
607 we split the EA cohorts into discovery and replication sets. The discovery cohorts consisted of 8288
608 participants from 10 cohorts, excluding FHS (n=2427) and ARIC (n=969), which were used as
609 replication cohorts. To build and replicate a prediction model, the DNAm data were preprocessed
610 utilizing the same strategy as in the EWAS analysis.

611 **Input features:** To evaluate the prediction performance of clinical risk factors and DNAm
612 comprehensively, we tested 13 sets of features, Feature set 1 (**F1**) included age (years), sex (male as 1

613 and female as 2), and 12 other clinical risk factors including BMI (kg/m²), smoking (current smoker
614 as 1, and former and never smoker as 0), alcohol consumption (grams/day), physical activity (MET
615 scores), educational attainment (education years), and prevalent diseases (yes as 1 and no as 0)
616 including hypertension, CHD, heart failure, stroke, type-2 diabetes, and cancer. **F2-F7** were mortality-
617 related CpGs selected by meta-analysis in the discovery cohorts by inverse-variance weighted
618 random-effects models at a series of p value thresholds, including **F2** CpGs at $P < 1e-7$, **F3** CpGs at
619 $P < 1e-6$, **F4** CpGs at $P < 1e-5$, **F5** CpGs at $P < 1e-4$, **F6** CpGs at $P < 1e-3$, and **F7** CpGs at $P < 0.05$. **F8-**
620 **F13** are **F1** (age, sex and 12 clinical phenotypes) plus **F2-F7** respectively. In doing so, we were able
621 to evaluate the prediction performance based on the clinical risk factors (**F1**) and the DNAm (**F2-F7**),
622 and test if the combination of DNAm with clinical risk factors (**F8-F13**) could be able to improve the
623 prediction performance by using clinical risk factors (**F1**) only and DNAm only (**F2-F7**).

624 **Model building:** We compared four methods of building prediction models, including 1) Elastic net -
625 Cox proportional hazards method (Elastic-coxph, using *glmnet*, a R package) (Friedman et al., 2010);
626 2) Random survival forest (RSF, using *randomForestSRC*, a R package) (Ishwaran et al., 2008); 3)
627 Cox-nnet (<https://github.com/lanagarmire/cox-nnet>, a Python package) (Ching et al., 2018), and 4)
628 DeepSurv (<https://github.com/jaredleekatzman/DeepSurv>, a Python package) (Katzman et al., 2018).
629 The first method is a penalized linear regression method, while the other three are non-linear machine
630 learning methods.

631 *Elastic-coxph* is a Cox regression model regularized with elastic net penalty (Friedman et al., 2010).
632 Performing this method requires to identify best values of two parameters, α and λ . We tuned each
633 model by iterating over a number of α and λ values under cross-validation. α indicated linearly
634 combined penalties of the lasso ($\alpha=0$) and ridge ($\alpha=1$) regression. λ is the shrinkage parameter, when
635 $\lambda=0$ indicated no shrinkage, and as λ increases, the coefficients are shrunk ever more strongly.
636 Effectively this will shrink some coefficients close to 0 for optimizing a set of features. The α value
637 was set to 0.5, and the λ value was set to lambda.min when training models.

638 *RSF* is an ensemble tree model that is based on the random forest method for survival analysis
639 (Ishwaran et al., 2008). The optimized values of parameters in RSF models, including the number of
640 trees (nTrees=100) and nodeSize =15 were chosen by iterating over a number of values which
641 maximized the accuracy of RSF models tested in the replication sets under cross-validation. RSF can
642 compute feature importance scores for feature selection.

643 *Cox-nnet* is an artificial neural network based method for survival analysis (Ching et al., 2018). Cox-
644 nnet includes two layer neural network: one hidden layer and one output layer. The output layer was
645 used to perform Cox regression based on the activation levels of the hidden layer. Cox-nnet could also
646 compute feature importance scores for feature selection. For each model training, the *L2*
647 regularization parameter is optimized using the *L2CVProfile* Python function by iterating over a
648 number of values under cross-validation.

649 *DeepSurv* is a deep learning-based survival prediction method (Katzman et al., 2018). DeepSurv uses
650 a multi-layer feed forward neural network, of which the hidden layers consist of a fully-connected
651 layer of nodes, followed by a dropout layer, and the output is a single node with a linear activation
652 which estimated the log-risk function in the Cox model, parameterized by the weight of the network.
653 The values of hyperparameters when using DeepSurv were *L2* regularization = 0.8, dropout = 0.4,
654 learning rate = 0.02, hidden layer size (4 layers with nodes 500, 200, 100 and 50), lr_decay = 0.001,
655 momentum = 0.9 and the activation method (using Scaled Exponential Linear Units), which were
656 optimized by iterating over a number of values each-by-each and under cross-validation. *DeepSurv*
657 has not been used previously for selecting features.

658 **Cross-validation:** The 2427 FHS participants were randomly split into 5 equal sets (n=485 or 486 in
659 each set), and each set included approximately equal numbers of deaths. We then used 3 of the 5 sets
660 (60%) for model training and the remaining 2 sets (40%) for model testing. In doing so, we obtained
661 10 combinations. In each training / testing combination, we constructed a model using the training
662 data, and then used the model to generate a mortality risk score based on the testing data. We assessed
663 associations of the predicted mortality risk score (after inverse normal transformation) with all-cause

664 mortality, CVD death, and cancer death in the testing data using time-to-event proportional hazards
665 models. This data partitioning and cross-validation strategy was only used to assess the robustness of
666 prediction models when using different features and methods, and to select the optimized parameters
667 for training models. The final models reported were built on all FHS participants using the optimized
668 parameters. We also repeated the same analysis steps using FHS participants without cancer at
669 baseline (n=2038; 238 deaths from all causes, 70 from CVD, and 42 from cancer).

670 ***Independent external validation:*** The prediction models built using all FHS participants were further
671 tested in ARIC EA participants for the prediction of mortality outcomes. We performed tests on all-
672 cause mortality and CVD death on all ARIC EA participants truncated at 15 years of follow up, and
673 tests on cancer death after excluding prevalent cancer.

674 ***Evaluation of model performance:*** We used four evaluation metrics to assess model performance,
675 including the concordance index (C-index) (Harrell Jr, Lee, & Mark, 1996), hazards ratio of predicted
676 risk score (inversely-transformed) for prediction of mortality, the integrated brier score (IBS) (Brier,
677 1950), and Kaplan-Meier (KM) survival curves for high, medium and low risk groups (Kaplan &
678 Meier, 1958). The C-index reflects the percentage of individuals whose predicted survival times are
679 correctly ordered. A C-index of 0.50 reflects no improvement in prediction over chance. The brier
680 score measures the mean of the difference between the observed and the estimated survival beyond a
681 certain time. The brier score ranges between 0 and 1, and a larger score indicates higher inaccuracy.
682 The integrated brier score is the brier score averaged over the entire time interval.

683 **DNAm Age**

684 We compared the prediction performance of DNAm age with our DNAm-based mortality prediction
685 model in relation to all-cause mortality, CVD death, and cancer death in the ARIC EA cohort
686 (truncating follow up at 15 years). Four measures of DNAm age were used in this study, including
687 PhenoAge (Levine et al., 2018), Horvath age (Horvath, 2013), Hannum age (Hannum et al., 2013) and
688 GrimAge (Lu et al., 2019). The Horvath Age is based on 353 CpGs, the Hannum age is based on 71
689 CpGs, and PhenoAge is based on 513 CpGs. DNAm age was calculated as the sum of the beta values

690 multiplied by the reported effect size. Due to the GrimAge model was not publicly available, the
691 GrimAge was calculated by uploading the DNAm data to the website
692 (<http://dnamage.genetics.ucla.edu/>). Proportional hazards regression models were used to test the
693 association between inversely-rank transformed DNAm age (all 3 approaches) and mortality
694 outcomes, adjusting for age, sex, and clinical covariates (see **Mortality ascertainment and clinical**
695 **phenotypes**).

696 **meQTLs**

697 meQTLs (SNPs associated with DNA methylation) were identified from 4170 FHS participants as
698 reported previously, including 4.7 million *cis*-meQTLs and 630K *trans*-meQTLs at $P < 2 \times 10^{-11}$ for *cis*
699 and $P < 1.5 \times 10^{-14}$ for *trans* (Huan et al., 2019). The genotypes were measured using Affymetrix SNP
700 500K mapping and Affymetrix 50K gene-focused MIP arrays. Genotypes were imputed using the
701 1000 Genomes Project panel phase 3 using MACH / Minimac software. SNPs with MAF > 0.01 and
702 imputation quality ratio > 0.3 were retained. *cis*-meQTLs were defined as SNPs residing within 1 Mb
703 upstream or downstream of a CpG site. The FHS meQTL data resource includes 3.5 times more *cis*-,
704 and 10 times more *trans*-meQTL SNPs than the other published studies to date
705 (https://ftp.ncbi.nlm.nih.gov/eqtl/original_submissions/FHS_meQTLs/).

706 **Mendelian randomization**

707 Two-sample Mendelian randomization (MR) was used to identify putatively causal CpGs for human
708 longevity, CVD and CVD risk factors, and cancer types using a multi-step strategy. Estimated
709 associations and effect sizes between SNPs and traits were based on the latest published GWAS meta-
710 analysis of human longevity (Deelen et al., 2019), coronary heart disease (CHD) (Nikpay et al., 2015);
711 myocardial infarction (MI) (Nikpay et al., 2015); type-II diabetes (T2D) (Scott et al., 2017); body
712 mass index (BMI) (Locke et al., 2015); lipids traits including high-density lipoprotein (HDL)
713 cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol (TC), and triglycerides (TG)
714 (Willer et al., 2013); systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Evangelou et
715 al., 2018), and cancer types including breast cancer (Michailidou et al., 2017), prostate cancer

716 (Schumacher et al., 2018), lung cancer (Wang et al., 2014) and ovarian cancer (Phelan et al., 2017).

717 We were unable to include some other popular cancer types, because their GWAS data were not be
718 accessible by us.

719 Instrumental variables (IVs) for each CpG site consisted of independent *cis*-meQTLs pruned at
720 linkage disequilibrium (LD) $r^2 < 0.01$, retaining only one *cis*-meQTL variant with the lowest SNP-CpG
721 P value in each LD block. LD proxies were defined using 1000 genomes imputation in EA. Inverse
722 variance weighted (IVW) MR tests were performed on CpGs with at least three independent *cis*-
723 meQTL variants, which is the minimum number of IVs needed to perform multiple instruments MR.
724 The multiple instruments improved the precision of IV estimates, and allowed the examination of
725 underlying IV assumption (Palmer et al., 2012). Among 177 all-cause mortality related CpGs at
726 $P < 1 \times 10^{-7}$, MR tests were performed on 17 CpGs having ≥ 3 independent *cis*-meQTL SNPs. To test the
727 validity of IVW-MR results, we performed heterogeneity and MR-EGGER pleiotropy tests for all IVs.
728 The statistical significance threshold for MR is $P_{MR} < 0.05/17$, and both P_{heter} and P_{pleio} were required to
729 be > 0.05 .

730 **eQTLs**

731 Association tests of DNAm and gene expression were performed in 3684 FHS participants with
732 available DNAm and gene expression data. mRNA was extracted from whole blood (collected in
733 PAXgene tubes) and profiled using the Affymetrix Human Exon 1.0 ST GeneChip platform. Raw
734 gene expression data were first normalized using the RMA (robust multi-array average) from
735 Affymetrix Power Tools (APT, [thermofisher.com/us/en/home/life-science/microarray-](http://thermofisher.com/us/en/home/life-science/microarray-analysis/affymetrix.html#1_2)
736 [analysis/affymetrix.html#1_2](http://thermofisher.com/us/en/home/life-science/microarray-analysis/affymetrix.html#1_2)) with quantile normalization. Then, output expression values of 17,318
737 genes were extracted by APT based on NetAffx annotation version 31.

738 DNAm β values were adjusted for age, sex, predicted blood cell fraction, the two top PCs of DNAm,
739 and 25 surrogate variables (SVs), with DNAm as a fixed effect, and batch as a random effect by
740 fitting LME models. Residuals (DNAm_resid) were retained. The gene expression values were
741 adjusted for age, sex, predicted blood cell fraction, a set of technical covariates, the two top PCs and

742 25 SVs, with gene expression as a fixed effect, and batch as a random effect by LME, and residuals
743 (mRNA_resid) were retained. Then, linear regression models were used to assess pair-wise
744 associations between DNAm_resid and mRNA_resid. SVs were calculated using the SVA package in
745 R. A *cis*-CpG-mRNA pair was defined as a CpG residing ± 1 Mb of the TSS of the corresponding gene
746 encoding the mRNA (*cis*-eQTM). The annotations of CpGs and transcripts were obtained from
747 annotation files of the HumanMethylation450K BeadChip and the Affymetrix exon array S1.0
748 platforms. We estimated that there were 1.6×10^8 potential *cis*-CpG-mRNA pairs. We only used *cis*-
749 eQTMs in this study because *trans*-eQTMs were not replicated in independent external studies. The
750 statistical significance threshold was $P < 3 \times 10^{-10}$ ($0.05 / 1.6 \times 10^8$)

751 **Gene ontology and pathway enrichment analysis**

752 Gene ontology and pathway enrichment analyses were performed on the genes annotated in relation to
753 the 177 all-cause mortality related CpGs at $P < 1 \times 10^{-7}$ or $P < 1 \times 10^{-5}$ as well as the *cis*-eQTM genes
754 associated with those CpGs. Hypergeometric tests were used to investigate over-representations of
755 genes from multiple biological process and pathways. To improve focus in this study, we only used
756 results of KEGG and Gene Ontology – biological process (GO-BP) terms. Enrichment tests used the
757 online DAVID Bioinformatics Resources 6.8 (<https://david.ncifcrf.gov/>). The P-value was further
758 corrected by the number of unique GO-BP terms and pathways. A Benjamini-Hochberg corrected
759 FDR < 0.2 was considered significant.

760

761 **Data Availability**

762 The DNA methylation data and phenotype data are available in dbGaP for some of the cohorts in this
763 study (<https://www.ncbi.nlm.nih.gov/gap/>) including FHS (accession number phs000724.v5.p10) and
764 WHI (accession number phs000200.v12.p3). For LBC, data are available in the European Genome-
765 phenome Archive (<https://www.ebi.ac.uk/ega/home>), under accession number EGAS00001000910.
766 For the other cohorts including ARIC, CHS, NAS, InCHIANTI, KORA, ESTHER, Danish, RS and

767 CARDIA, the data are available on request by contacting with the principal investigators of each
768 cohort.

769 **Declarations**

770 **Ethics approval and consent to participate**

771 This study included participants from 12 population-based cohorts studies, including the
772 Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the
773 Danish Twin Register sample (DTR), the Epidemiologische Studie zu Chancen der Verhütung,
774 Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung
775 (ESTHER), the Framingham Heart Study (FHS), the Invecchiare in Chianti (InCHIANTI) Study, the
776 Cooperative Health Research in the Region of Augsburg (KORA F4), the Lothian Birth Cohorts of
777 1921 (LBC1921) and 1936 (LBC1936), the Normative Aging Study (NAS), the Rotterdam Study
778 (RS), and Women’s Health Initiative (WHI). All of the 12 studies were approved by their institutional
779 review committees (see details in **Additional file 1**). All study participants provided written informed
780 consent.

781 **Acknowledgements**

782 The views expressed in this manuscript are those of the authors and do not necessarily represent the
783 views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S.
784 Department of Health and Human Services.

785 For a list of all the investigators who have contributed to WHI science, please visit: <https://s3-us-west-2.amazonaws.com/www-whi-org/wp-content/uploads/WHI-Investigator-Long-List.pdf>.

787 **Funding**

788 The **Framingham Heart Study** is funded by National Institutes of Health contract N01-HC-25195
789 and HHSN268201500001I. The laboratory work for this investigation was funded by the Division of
790 Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health. The

791 analytical component of this project was funded by the Division of Intramural Research, National
792 Heart, Lung, and Blood Institute, and the Center for Information Technology, National Institutes of
793 Health, Bethesda, MD.

794 The **Cardiovascular Health Study** is supported by NHLBI contracts HHSN268201200036C,
795 HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080,
796 N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295,
797 U01HL130114, K08HL116640, R01HL087652, R01HL092111, R01HL103612, R01HL105756,
798 R01HL103612, R01HL111089, R01HL116747 and R01HL120393 with additional contribution from
799 the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was
800 provided through R01AG023629 from the National Institute on Aging (NIA), Merck Foundation /
801 Society of Epidemiologic Research as well as Laughlin Family, Alpha Phi Foundation, and Locke
802 Charitable Foundation. A full list of principal CHS investigators and institutions can be found at
803 CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for
804 Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes
805 and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern
806 California Diabetes Endocrinology Research Center. Infrastructure for the CHARGE Consortium is
807 supported in part by the National Heart, Lung, and Blood Institute grant R01HL105756.

808 The **DTR** study was supported by The Danish Council for Independent Research—Medical Sciences
809 (DFF-6110-00016), the European Union’s Seventh Framework Programme (FP7/2007–2011) under
810 grant Agreement No. 259679 and The Danish National Program for Research Infrastructure 2007 (09-
811 063256).

812 The **WHI** program is funded by the National Heart, Lung, and Blood Institute, National Institutes of
813 Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C,
814 HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.
815 Work in WHI was NIEHS-supported by R01-ES020836 (EAW; AB; LH).

816 Phenotype collection in the **Lothian Birth Cohort 1921** was supported by the UK's Biotechnology
817 and Biological Sciences Research Council (BBSRC), The Royal Society and The Chief Scientist
818 Office of the Scottish Government. Phenotype collection in the **Lothian Birth Cohort 1936** was
819 supported by Age UK (The Disconnected Mind project). Methylation typing was supported by Centre
820 for Cognitive Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, The Wellcome Trust
821 Institutional Strategic Support Fund, The University of Edinburgh, and The University of Queensland.
822 IJD is a member of the University of Edinburgh Centre for Cognitive Ageing and Cognitive
823 Epidemiology (CCACE), which is supported by funding from the BBSRC, the Medical Research
824 Council (MRC), and the University of Edinburgh as part of the cross-council Lifelong Health and
825 Wellbeing initiative (MR/K026992/1). W.D.H. is supported by a grant from Age UK (Disconnected
826 Mind Project).

827

828 **Authors' contributions**

829 T. H., D.L., and J.P. designed, directed, and supervised the project. T. H., and D.L. drafted the
830 manuscript. T.H., S.N., E.C., C. R., D.H., J.B., M.S., Y.Z., A.B., E.M., and T.T. conducted the
831 analyses. All authors participated in revising and editing the manuscripts. All authors have read and
832 approved the final version of the manuscript.

833 **Competing Interests**

834 The authors declare no conflict of interest.

835

836

Table 1: Clinical characteristics the 15,013 study participants.

Cohort	Total N	No. of all-cause death	No. of CVD death	No. of cancer death	Time to death / last follow-up years, mean (SD)	Age, mean (SD)	Sex (F, %)	BMI, mean (SD)	Prevalent Diseases					
									Type 2 Diabetes (n)	Coronary Heart Disease (n)	Heart Failure (n)	Stroke (n)	Hypertension (n)	Cancer (n)
-- European Ancestry														
ARIC	969	331	95	94	20.0 (5.2)	59.8 (5.5)	59	26.2 (4.5)	86	44	29	16	233	102
CHS	419	373	132		12.7 (6.1)	75.0 (4.9)	60	26.8 (4.9)	72	16	11	5	224	78
DTR	870	298	74	40	9.3 (3.4)	69.4 (7.9)	52	25.9 (3.9)	46*			37	269	129
ESTHER	1000	265	94	90	13.7 (3.5)	62.1 (6.5)	50	27.8 (4.3)	154	144	110	28	572	77
FHS	2427	403	91	155	9.1 (2.2)	66.3 (9.0)	55	28.3 (5.3)	279	226	53	116	107	389
InCHIANTi	488	104			10.0 (1.6)	62.4 (15.8)	52	27.0 (3.9)	42	31	9	10	232	
KORA F4	1727	89	31	35	6.4 (0.9)	61.0 (8.9)	51	28.1 (4.8)	158	105	41	47	789	154
LBC 1921	418	366			9.8 (4.7)	79.1 (0.6)	60	28.2 (4.0)	19	70		33	170	
LBC 1936	900	192			10.2 (2.4)	69.6 (0.8)	50	27.7(4.4)	72	221		46	364	
NAS	640	221	123	72	10.5 (3.3)	72.8 (6.8)	0	28.1 (4.0)	117	181		42	447	316
RS	731	73			6.8 (1.5)	59.9 (8.2)	54	27.4 (4.5)	74	45		30	385	76
WHI	1095	192	48	60	11.5 (3.5)	62 (6.9)	100	28.8 (5.9)	60	20	5	11	469	14
-- African Ancestry														
ARIC	2446	1069	424	322	18.6 (6.6)	56.5 (5.8)	64	30.1 (6.2)	643	120	163	75	1373	87
CHS	325	264	96		12.9 (6.6)	73.1 (5.5)	62	28.6 (5.2)	68	2	0	2	235	36
WHI	558	74	27		10.6 (3.7)	61 (6.8)	100	31.5 (6.1)	76	18	11	12	369	2

*The diabetes cases in DTR included both type-I and type-II diabetes.

The clinical risk factors were ascertained at the time of blood draw for DNAm measurements. BMI was calculated as weight (kg) divided by height squared (m²). Diabetes was defined as a measured fasting blood glucose level of >125 mg/dL or current use of glucose-lowering prescription medication. Hypertension was defined as a measured systolic blood pressure (BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg or use of antihypertensive prescription medication. Cancer was defined as the occurrence of any type of cancer excluding non-melanoma skin cancer.

Table 2: Trans-ethnic replicated all-cause mortality related CpGs.

CpG	Chr	Position	Gene	Meta-analysis EA cohorts		Meta-analysis AA cohorts		Transethnic replication Bonferroni corrected P
				HR (95% CI)	P-value	HR (95% CI)	P-value	
-- Discovered in EA, and then replicated in AA								
cg16743273	19	2076833	<i>MOBKL2</i> A	1.15 (1.1-1.21)	1.57E-09	1.24 (1.15-1.33)	1.28E-08	2.08E-06
cg18181703	17	76354621	<i>SOCS3</i>	0.83 (0.8-0.87)	6.15E-16	0.82 (0.77-0.88)	3.71E-08	6.05E-06
cg21393163	1	12217629		0.84 (0.8-0.88)	4.15E-12	0.84 (0.79-0.89)	7.48E-08	1.22E-05
cg15310871	8	20077936	<i>ATP6V1B</i> 2	1.18 (1.12-1.25)	1.42E-08	1.19 (1.11-1.26)	1.80E-07	2.94E-05
cg25953130	10	63753550	<i>ARID5B</i>	0.87 (0.83-0.91)	4.67E-10	0.86 (0.81-0.91)	1.22E-06	1.98E-04
cg05438378	15	67383736	<i>SMAD3</i>	0.88 (0.84-0.92)	1.52E-08	0.85 (0.79-0.91)	3.68E-06	6.00E-04
cg26470501	19	45252955	<i>BCL3</i>	0.84 (0.79-0.88)	8.38E-12	0.81 (0.74-0.89)	1.48E-05	2.42E-03
cg06126421	6	30720080		0.8 (0.75-0.86)	2.48E-10	0.84 (0.78-0.91)	1.69E-05	2.75E-03
cg02003183	14	103415882	<i>CDC42BP</i> B	1.19 (1.13-1.26)	1.94E-11	1.16 (1.08-1.24)	2.00E-05	3.26E-03
cg10950251	1	204466432		0.86 (0.82-0.91)	4.05E-08	0.86 (0.8-0.92)	2.34E-05	3.81E-03
cg17501210	6	166970252	<i>RPS6KA2</i>	0.86 (0.81-0.9)	5.84E-09	0.87 (0.82-0.93)	2.71E-05	4.41E-03
cg23598089	1	203652079	<i>ATP2B4</i>	1.13 (1.08-1.18)	2.36E-08	1.14 (1.07-1.22)	4.19E-05	6.84E-03
cg21993290	2	233703120	<i>GIGYF2</i>	0.88 (0.84-0.92)	6.13E-08	0.87 (0.81-0.93)	4.94E-05	8.06E-03
cg04987734	14	103415873	<i>CDC42BP</i> B	1.2 (1.15-1.26)	2.53E-14	1.15 (1.07-1.23)	5.77E-05	9.41E-03
cg20813374	6	35657180	<i>FKBP5</i>	0.84 (0.78-0.89)	4.27E-08	0.84 (0.77-0.91)	7.19E-05	1.17E-02
cg11927233	5	170816542	<i>NPM1</i>	0.84 (0.8-0.89)	2.43E-09	0.89 (0.84-0.95)	2.41E-04	3.92E-02
cg24859433	6	30720203		0.85 (0.81-0.9)	7.15E-10	0.88 (0.82-0.94)	2.70E-04	4.40E-02
cg01445100	16	88103339	<i>BANP</i>	1.23 (1.15-1.32)	1.88E-09	1.24 (1.1-1.39)	2.76E-04	4.49E-02
-- Discovered in AA, and then replicated in EA								
cg18181703	17	76354621	<i>SOCS3</i>	0.83 (0.8-0.87)	6.15E-16	0.82 (0.77-0.88)	3.71E-08	1.04E-14
cg21393163	1	12217629		0.84 (0.8-0.88)	4.15E-12	0.84 (0.79-0.89)	7.48E-08	7.05E-11
cg16743273	19	2076833	<i>MOBKL2</i> A	1.15 (1.1-1.21)	1.57E-09	1.24 (1.15-1.33)	1.28E-08	2.67E-08
cg25114611	6	35696870	<i>FKBP5</i>	0.86 (0.81-0.91)	7.50E-07	0.81 (0.75-0.87)	1.79E-08	1.28E-05
cg16411857	16	57023191	<i>NLRCS</i>	0.88 (0.84-0.93)	4.40E-06	0.79 (0.74-0.85)	2.40E-11	7.47E-05
cg16936953	17	57915665	<i>TMEM49</i>	0.91 (0.87-0.95)	7.05E-05	0.82 (0.77-0.88)	1.72E-08	1.20E-03
cg23570810	11	315102	<i>IFITM1</i>	0.86 (0.8-0.93)	9.75E-05	0.77 (0.72-0.83)	2.35E-11	1.66E-03
cg12054453	17	57915717	<i>TMEM49</i>	0.92 (0.88-0.96)	1.57E-04	0.84 (0.79-0.89)	2.93E-08	2.66E-03
cg18942579	17	57915773	<i>TMEM49</i>	0.91 (0.87-0.96)	3.53E-04	0.8 (0.74-0.86)	2.58E-09	6.01E-03
cg01041239	18	13222581	<i>Clorf1</i>	1.1 (1.04-1.16)	1.29E-03	1.22 (1.14-1.31)	1.04E-08	2.20E-02
cg03038262	11	315262	<i>IFITM1</i>	0.88 (0.82-0.96)	1.85E-03	0.72 (0.66-0.79)	5.14E-13	3.15E-02
cg24408769	6	15506085	<i>JARID2</i>	1.11 (1.04-1.18)	2.17E-03	1.27 (1.17-1.37)	1.29E-08	3.68E-02

Abbreviation: HR, hazard ratio per standard deviation; CI, confidence interval; EA, European ancestry; AA, African ancestry.

Table 3: Performance robustness comparison of mortality predictors in FHS and ARIC cohorts.

Model	FHS*			ARIC [†]		
	HR	C-index	IBS	HR (95% CI)	C-index	IBS
<i>-- All-cause mortality</i>						
Clinical Risk Factor Model	3.37	0.80	0.07	2.64 (2.21-3.15)	0.75	0.04
CpG Model	2.91	0.77	0.07	2.24 (1.89-2.66)	0.72	0.04
Integrative Model	3.50	0.80	0.06	2.95 (2.45-3.55)	0.77	0.04
<i>-- CVD Death</i>						
Clinical Risk Factor Model	3.74	0.81	0.02	3.51 (2.57-4.79)	0.81	0.02
CpG Model	3.85	0.82	0.02	2.62 (1.56-3.91)	0.77	0.02
Integrative Model	3.90	0.83	0.02	3.65 (2.63-5.05)	0.80	0.02
<i>-- Cancer Death (excluding prevalent cancer cases)</i>						
Clinical Risk Factor Model	1.25	0.57	0.01	2.35 (1.74-3.18)	0.71	0.02
CpG Model	1.71	0.65	0.01	2.22 (1.64-2.89)	0.73	0.02
Integrative Model	1.78	0.68	0.01	2.58 (1.90-3.50)	0.76	0.02

Abbreviation: HR, hazard ratio per standard deviation; IBS: Integrated brier score;

* HR, C-index and IBS values in FHS reflect the average values of 10 times cross-validation.

[†]The results were obtained from ARIC European ancestry participants with follow up truncated at 15 years.

The clinical risk factor models were trained by using clinical risk factors as the sole input features. The CpG Models were trained by using CpGs selecting in the discovery meta-analysis. The integrative model was trained by using both clinical risk factors and CpGs selecting in the discovery meta-analysis.

The Clinical Risk Factor Model used to predict all-cause mortality and CVD death was shown in **Table S10**, and to predict cancer death (trained in samples excluding prevalent cancer cases) was shown in **Table S11**. The CpG model used to predict all-cause mortality and CVD death was shown in **Table S12**, and to predict cancer death (trained in samples excluding prevalent cancer cases) was shown in **Table S13**. The integrative model used to predict all-cause mortality and CVD death was shown in **Table S14**, and to predict cancer death (trained in samples excluding prevalent cancer cases) was shown in **Table S15**.

Figure Legends

Figure 1: The effect sizes (log hazards ratios) and 95% confidence intervals of CpGs related to mortality identified by meta-analysis, comparing the results for all-cause mortality, CVD death, and cancer death. A) Results of meta-analysis of European ancestry (EA); B) Results of meta-analysis of African ancestry (AA). These figures showed the CpGs associated with all-cause mortality identified by the meta-analysis, which were also associated with either CVD death or cancer death passing Bonferroni corrected threshold. Figure 1A shows 51 CpGs in EA, including 41 CpGs associated with CVD death, 16 with cancer death, and 5 with both. Figure 1B shows 16 CpGs in AA, including 15 CpGs associated with CVD death, 8 with cancer death, and 7 with both.


Figure 2: Kaplan–Meier estimates of mortality risk scores with respect to mortality outcomes in ARIC study. A) survival curves with respect to all-cause mortality; B) survival curves with respect to CVD death; C) survival curves with respect to cancer death. The results were obtained from ARIC European ancestry participants with follow up truncated at 15 years. For cancer death, we excluded samples who had any type of cancer before blood drawn for DNA methylation measurements. The mortality risk scores for A) and B) were computed by the model (**Table S10**), and for C) was computed by the model (**Table S11**)

Figure 3: Hazard ratios per standard deviation increment with 95% confidence intervals for mortality. A) with respect to all-cause mortality; B) with respect to CVD death; C) with respect to cancer death. The results were obtained from ARIC European ancestry participants with follow up truncated at 15 years. For cancer death, samples who had any type of cancer before blood drawn for DNA methylation measurements were excluded. Cox regression models were used to relate mortality outcomes to inversely-transformed mortality risk scores computed by Integrative models (**Table S12-S13**) and CpG models (**Table S10-S11**), and inversely-transformed DNAm age including GrimAge (Lu et al., 2019), PhenoAge(Levine et al., 2018), Horvath Age(Horvath, 2013), and Hannum Age(Hannum et al., 2013). *Adj age and sex* indicated the association further adjusted for age and sex.

Adj age, sex and risk factors indicated the association further adjusted for age, sex and the other clinical risk factors.

Figure 1

A



B






Figure 2

A



B



C






Figure 3


A



B



C



References

- Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., . . . Eppig, J. T. (2000). Gene ontology: tool for the unification of biology. *Nature genetics*, 25(1), 25-29.
- Brier, G. W. (1950). Verification of forecasts expressed in terms of probability. *Monthly weather review*, 78(1), 1-3.
- Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., . . . Sollis, E. (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic acids research*, 47(D1), D1005-D1012.
- Chen, B. H., Marioni, R. E., Colicino, E., Peters, M. J., Ward-Caviness, C. K., Tsai, P.-C., . . . Guan, W. (2016). DNA methylation-based measures of biological age: meta-analysis predicting time to death. *Aging (Albany NY)*, 8(9), 1844.
- Ching, T., Zhu, X., & Garmire, L. X. (2018). Cox-nnet: an artificial neural network method for prognosis prediction of high-throughput omics data. *PLoS computational biology*, 14(4), e1006076.
- Colicino, E., Marioni, R., Ward-Caviness, C., Gondalia, R., Guan, W., Chen, B., . . . Golareh, A. (2020). Blood DNA methylation sites predict death risk in a longitudinal study of 12,300 individuals. *Aging (Albany NY)*, 12(14), 14092.
- Deelen, J., Evans, D. S., Arking, D. E., Tesi, N., Nygaard, M., Liu, X., . . . Atzmon, G. (2019). A meta-analysis of genome-wide association studies identifies multiple longevity genes. *Nature Communications*, 10(1), 1-14.
- Devlin, B., Roeder, K., & Wasserman, L. (2001). Genomic control, a new approach to genetic-based association studies. *Theoretical population biology*, 60(3), 155-166.
- Dugué, P. A., Bassett, J. K., Joo, J. E., Jung, C. H., Ming Wong, E., Moreno-Betancur, M., . . . Severi, G. (2018). DNA methylation-based biological aging and cancer risk and survival: Pooled analysis of seven prospective studies. *International journal of cancer*, 142(8), 1611-1619.
- Evangelou, E., Warren, H. R., Mosen-Ansorena, D., Mifsud, B., Pazoki, R., Gao, H., . . . Karaman, I. (2018). Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nature genetics*, 50(10), 1412-1425.
- Feng, T., Chen, Z., Gu, J., Wang, Y., Zhang, J., & Min, L. (2019). The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma. *Lung Cancer*, 137, 19-22.
- Friedman, J., Hastie, T., & Tibshirani, R. (2010). Regularization paths for generalized linear models via coordinate descent. *Journal of statistical software*, 33(1), 1.
- Gong, J., Li, Y., Liu, C.-j., Xiang, Y., Li, C., Ye, Y., . . . Diao, L. (2017). A pan-cancer analysis of the expression and clinical relevance of small nucleolar RNAs in human cancer. *Cell reports*, 21(7), 1968-1981.
- Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sada, S., . . . Gao, Y. (2013). Genome-wide methylation profiles reveal quantitative views of human aging rates. *Molecular cell*, 49(2), 359-367.
- Harrell Jr, F. E., Lee, K. L., & Mark, D. B. (1996). Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Statistics in medicine*, 15(4), 361-387.
- Ho, J. E., Lyass, A., Courchesne, P., Chen, G., Liu, C., Yin, X., . . . Levy, D. (2018). Protein biomarkers of cardiovascular disease and mortality in the community. *Journal of the American Heart Association*, 7(14), e008108.
- Horvath, S. (2013). DNA methylation age of human tissues and cell types. *Genome biology*, 14(10), 3156.

- Horvath, S., Pirazzini, C., Bacalini, M. G., Gentilini, D., Di Blasio, A. M., Delledonne, M., . . . Passarino, G. (2015). Decreased epigenetic age of PBMCs from Italian semi-supercentenarians and their offspring. *Aging (Albany NY)*, 7(12), 1159.
- Huan, T., Joehanes, R., Song, C., Peng, F., Guo, Y., Mendelson, M., . . . Richard, M. (2019). Genome-wide identification of DNA methylation QTLs in whole blood highlights pathways for cardiovascular disease. *Nature Communications*, 10(1), 1-14.
- Ishwaran, H., Kogalur, U. B., Blackstone, E. H., & Lauer, M. S. (2008). Random survival forests. *The annals of applied statistics*, 2(3), 841-860.
- Joehanes, R., Just, A. C., Marioni, R. E., Pilling, L. C., Reynolds, L. M., Mandaviya, P. R., . . . Aslibekyan, S. (2016). Epigenetic signatures of cigarette smoking. *Circulation: Cardiovascular Genetics*, 9(5), 436-447.
- Jones, P. A., & Takai, D. (2001). The role of DNA methylation in mammalian epigenetics. *Science*, 293(5532), 1068-1070.
- Kanehisa, M., & Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. *Nucleic acids research*, 28(1), 27-30.
- Kaplan, E. L., & Meier, P. (1958). Nonparametric estimation from incomplete observations. *Journal of the American statistical association*, 53(282), 457-481.
- Katzman, J. L., Shaham, U., Cloninger, A., Bates, J., Jiang, T., & Kluger, Y. (2018). DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. *BMC medical research methodology*, 18(1), 24.
- Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., . . . Li, Y. (2018). An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*, 10(4), 573.
- Liu, C., Marioni, R. E., Hedman, Å. K., Pfeiffer, L., Tsai, P.-C., Reynolds, L. M., . . . Tanaka, T. (2018). A DNA methylation biomarker of alcohol consumption. *Molecular psychiatry*, 23(2), 422-433.
- Locke, A. E., Kahali, B., Berndt, S. I., Justice, A. E., Pers, T. H., Day, F. R., . . . Yang, J. (2015). Genetic studies of body mass index yield new insights for obesity biology. *Nature*, 518(7538), 197-206.
- Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., . . . Stewart, J. D. (2019). DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY)*, 11(2), 303.
- Ma, J., Rebholz, C. M., Braun, K. V., Reynolds, L. M., Aslibekyan, S., Xia, R., . . . Mendelson, M. M. (2020). Whole Blood DNA Methylation Signatures of Diet Are Associated with Cardiovascular Disease Risk Factors and All-cause Mortality. *Circulation: Genomic and Precision Medicine*.
- Maksimovic, J., Gordon, L., & Oshlack, A. (2012). SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. *Genome biology*, 13(6), 1-12.
- Marioni, R. E., Shah, S., McRae, A. F., Chen, B. H., Colicino, E., Harris, S. E., . . . Cox, S. R. (2015). DNA methylation age of blood predicts all-cause mortality in later life. *Genome biology*, 16(1), 25.
- Marioni, R. E., Shah, S., McRae, A. F., Ritchie, S. J., Muniz-Terrera, G., Harris, S. E., . . . Pattie, A. (2015). The epigenetic clock is correlated with physical and cognitive fitness in the Lothian Birth Cohort 1936. *International journal of epidemiology*, 44(4), 1388-1396.
- Mendelson, M. M., Marioni, R. E., Joehanes, R., Liu, C., Hedman, Å. K., Aslibekyan, S., . . . Yao, C. (2017). Association of body mass index with DNA methylation and gene expression in blood cells and relations to cardiometabolic disease: a Mendelian randomization approach. *PLoS medicine*, 14(1).
- Michailidou, K., Lindström, S., Dennis, J., Beesley, J., Hui, S., Kar, S., . . . Rostamianfar, A. (2017). Association analysis identifies 65 new breast cancer risk loci. *Nature*, 551(7678), 92.
- Nikpay, M., Goel, A., Won, H.-H., Hall, L. M., Willenborg, C., Kanoni, S., . . . Hopewell, J. C. (2015). A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nature genetics*, 47(10), 1121.

- Palmer, T. M., Lawlor, D. A., Harbord, R. M., Sheehan, N. A., Tobias, J. H., Timpson, N. J., . . . Sterne, J. A. (2012). Using multiple genetic variants as instrumental variables for modifiable risk factors. *Statistical methods in medical research*, *21*(3), 223-242.
- Patterson, D. G., Roberts, J. T., King, V. M., Houserova, D., Barnhill, E. C., Crucello, A., . . . Nguyen, M. (2017). Human snoRNA-93 is processed into a microRNA-like RNA that promotes breast cancer cell invasion. *NPJ Breast Cancer*, *3*(1), 1-12.
- Phelan, C. M., Kuchenbaecker, K. B., Tyrer, J. P., Kar, S. P., Lawrenson, K., Winham, S. J., . . . Chornokur, G. (2017). Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature genetics*, *49*(5), 680.
- Pidsley, R., Wong, C. C., Volta, M., Lunnon, K., Mill, J., & Schalkwyk, L. C. (2013). A data-driven approach to preprocessing Illumina 450K methylation array data. *BMC genomics*, *14*(1), 1-10.
- Pilling, L. C., Kuo, C.-L., Sicinski, K., Tamosauskaite, J., Kuchel, G. A., Harries, L. W., . . . Melzer, D. (2017). Human longevity: 25 genetic loci associated in 389,166 UK biobank participants. *Aging (Albany NY)*, *9*(12), 2504.
- Richard, M. A., Huan, T., Lighthart, S., Gondalia, R., Jhun, M. A., Brody, J. A., . . . Tsai, P.-C. (2017). DNA methylation analysis identifies loci for blood pressure regulation. *The American Journal of Human Genetics*, *101*(6), 888-902.
- Schumacher, F. R., Al Olama, A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders, E. J., . . . Cieza-Borrella, C. (2018). Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature genetics*, *50*(7), 928.
- Scott, R. A., Scott, L. J., Mägi, R., Marullo, L., Gaulton, K. J., Kaakinen, M., . . . Eicher, J. D. (2017). An expanded genome-wide association study of type 2 diabetes in Europeans. *Diabetes*, *66*(11), 2888-2902.
- Shah, R. V., Hwang, S.-J., Yeri, A., Tanriverdi, K., Pico, A. R., Yao, C., . . . Demarco, D. (2019). Proteins altered by surgical weight loss highlight biomarkers of insulin resistance in the community. *Arteriosclerosis, thrombosis, and vascular biology*, *39*(1), 107-115.
- Svane, A. M., Soerensen, M., Lund, J., Tan, Q., Jylhävä, J., Wang, Y., . . . Deary, I. J. (2018). DNA methylation and all-cause mortality in middle-aged and elderly Danish twins. *Genes*, *9*(2), 78.
- Teschendorff, A. E., Marabita, F., Lechner, M., Bartlett, T., Tegner, J., Gomez-Cabrero, D., & Beck, S. (2013). A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics*, *29*(2), 189-196.
- Timmers, P. R., Mounier, N., Lall, K., Fischer, K., Ning, Z., Feng, X., . . . Esko, T. (2019). Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances. *eLife*, *8*, e39856.
- Triche Jr, T. J., Weisenberger, D. J., Van Den Berg, D., Laird, P. W., & Siegmund, K. D. (2013). Low-level processing of Illumina Infinium DNA methylation beadarrays. *Nucleic acids research*, *41*(7), e90-e90.
- van den Berg, N., Beekman, M., Smith, K. R., Janssens, A., & Slagboom, P. E. (2017). Historical demography and longevity genetics: back to the future. *Ageing research reviews*, *38*, 28-39.
- Van Eyken, E., Van Laer, L., Franssen, E., Topsakal, V., Lemkens, N., Laureys, W., . . . Van De Heyning, P. (2006). KCNQ4: a gene for age-related hearing impairment? *Human mutation*, *27*(10), 1007-1016.
- Walter, S., Atzmon, G., Demerath, E. W., Garcia, M. E., Kaplan, R. C., Kumari, M., . . . Tranah, G. J. (2011). A genome-wide association study of aging. *Neurobiology of aging*, *32*(11), 2109.e2115-2109.e2128.
- Wang, Y., McKay, J. D., Rafnar, T., Wang, Z., Timofeeva, M. N., Broderick, P., . . . Han, Y. (2014). Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. *Nature genetics*, *46*(7), 736.
- Willer, C. J., Schmidt, E. M., Sengupta, S., Peloso, G. M., Gustafsson, S., Kanoni, S., . . . Mora, S. (2013). Discovery and refinement of loci associated with lipid levels. *Nature genetics*, *45*(11), 1274.

- Yao, C., Chen, G., Song, C., Keefe, J., Mendelson, M., Huan, T., . . . Wu, H. (2018). Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. *Nature Communications*, *9*(1), 1-11.
- Zhang, Y., Wilson, R., Heiss, J., Breitling, L. P., Saum, K.-U., Schöttker, B., . . . Brenner, H. (2017). DNA methylation signatures in peripheral blood strongly predict all-cause mortality. *Nature Communications*, *8*(1), 1-11.
- Zhao, Y., Yan, Y., Ma, R., Lv, X., Zhang, L., Wang, J., . . . Zhao, L. (2020). Expression signature of six-snoRNA serves as novel non-invasive biomarker for diagnosis and prognosis prediction of renal clear cell carcinoma. *Journal of cellular and molecular medicine*, *24*(3), 2215-2228.